Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Altimmune appointed Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026, as part of a planned succession tied to its transition into a late-stage clinical company. Greenleaf is a former CEO of Aurinia and Sucampo Pharmaceuticals; Howarth most recently served as CFO of Madrigal Pharmaceuticals, which launched the first approved MASH treatment. Directors John M. Gill, Mitchel Sayare, and Klaus O.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.